Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer

Thrombosis and Haemostasis

Volumn 114, Issue 1, 2015, Pages 150-157

  Schulman, Sam ^a,b   Goldhaber, Samuel Z ^c   Kearon, Clive ^a   Kakkar, Ajay K ^d   Schellong, Sebastian ^e   Eriksson, Henry ^f   Hantel, Stefan ^g   Feuring, Martin ^g   Kreuzer, Jörg ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bleeding; Cancer; Recurrence; Thrombin inhibitor; Venous thromboembolism; Vitamin K antagonist

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; NEOPLASM; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; VENOUS THROMBOEMBOLISM; ADULT; AGED; BLOOD; CHEMICALLY INDUCED; COMPLICATION; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBINS; DABIGATRAN; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84934759278     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0977     Document Type: Article

References (17)

1. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
2. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133: 454-545.
4. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2189-2204.
5. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
6. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S-94S.
7. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7: CD006650.
8. Rahme E, Feugere G, Sirois C, et al. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res 2013; 131: 210-217.
9. Larsen TB, Nielsen PB, Skjoth F, et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014; 9: e114445.
10. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute symptomatic venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
11. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
12. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
14. Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomised trial. Ann Intern Med 2011; 155: 653-659.
15. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
16. Harmsen S, Meijerman I, Febus CL, et al. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol 2010; 66: 765-771.
17. Harmsen S, Meijerman I, Maas-Bakker RF, et al. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. Eur J Pharm Sci 2013; 48: 644-649.